Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06291012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stopping Pneumonia Antibiotherapy Regimen Early

Study acronym: SPARE
StatusNot Yet Recruiting
PhasePhase 4
Started2024-09-01
View on ClinicalTrials.gov ↗

Amendment history

2024-05-17
Study Status, Outcome Measures, Eligibility v1
Eligibility criteria+105 characters
[...] e people with a body mass index (BMI) ≥ the 97th percentile Asthma with basic treatment Wheezing during the episode Presence of pleural effusion on [...] e to obtain informed consent by the legal representative(s) Patient whose legal representatives are unable to read/write french language Patient not affiliated with or not benefiting from a nationa [...]
Secondary endpointsdetails revised at 1 of 4 entries
2024-02-26
Original filing
The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days.
Trial Details
NCT Number NCT06291012
Lead Sponsor University Hospital, Montpellier
Collaborators: Direction Générale de l'Offre de Soins
Conditions Community-acquired Pneumonia, Child, Only
Enrollment 1,100 participants
Start Date 2024-09-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-20